Board of Directors
Elkan Gamzu, Ph.D., Chairman
Burt Adelman, M.D.
Neal Farber, Ph.D..
Daniel Katzman, M.Sc.
Karen Talmadge, Ph.D., Observer

Board of Directors

Elkan Gamzu, Ph.D., Chairman of the Board, Acting Head of Clinical Trials
Dr. Gamzu has worked in the biopharmaceutical industry since 1971, in discovery with Hoffmann La Roche, in clinical management and drug development with Warner-Lambert, where as VP, Drug Development had responsibility for the development of Cognex, the first drug approved for Alzheimer's, and Neurontin. Dr. Gamzu served as CEO of Cambridge Neuroscience and as Interim VP of Development Project Leadership for Millennium Pharmaceuticals. He is a co-founder of BioPharmAnalysis, LLC, a company offering due diligence services and currently serves as Principal of enERGetics, LLC, a biopharmaceutical consulting company. Dr. Gamzu currently serves the boards of directors of Pharmos Corp. (NASDAQ: PARS) and Neurotech S.A.

Burt Adelman, M.D.
Burt A. Adelman M.D. was most recently Executive Vice President, Portfolio Strategy at Biogen Idec. Previously he held the position of EVP, R&D, and VP of Medical Research. He began his career with Biogen, Inc. in 1991 as Director of Medical Research, and held positions of increasing responsibility including VP, Regulatory Affairs, and VP, Development Operations. Dr. Adelman has served as a lecturer in medicine at the Harvard Medical School, Associate Professor of Medicine at the Medical College of Virginia, and Chief of Hematology at the Hunter Holmes McGuire VA Medical Center. He received his M.D. from Cornell Medical College.

Neal M. Farber, Ph.D., Chief Executive Officer
Dr. Farber has over 20 years experience in the biopharmaceutical industry in areas of research and product development. As President and CEO of Collgard Biopharmaceuticals, he raised $7 MM in a series A financing; completed a $40 MM corporate deal with a medical device company; initiated Phase I and II clinical trials in autoimmune and cancer programs; and signed development agreements with the NCI, EORTC, Mayo Clinic and the Walter Reed Army Hospital. Previously, Dr. Farber held senior corporate development positions at Biogen, Cubist Pharmaceuticals, and T Cell Sciences. Dr. Farber was a Helen Hay Whitney Research Fellow at Harvard University and received his PhD (Hammett Award) from Columbia University.

Daniel Katzman M.Sc., President and Founder
Mr. Katzman has over ten years of experience in the life sciences industry. Before founding NeuroHealing he served as VP of Business Development at Oridion Medical Ltd, a publicly traded company (Zurich SWX: ORIDN). By leading one of Oridion’s two divisions, Mr. Katzman supervised clinical trials, regulatory approval, intellectual property and marketing. Additionally, he has been granted four US patents, has led a pivotal, multi-center Phase III study and has obtained FDA approval for a drug-device combination product which included an NDA and a 510(k). Mr. Katzman received his graduate degree in Biochemistry from Universidad Nacional de La Plata, Argentina,

Karen Talmadge, Ph.D., Observer
Karen Talmadge, PhD is a Board observer representing the investors of Life Science Angels, LLC and co-chairs their biotechnology company screening committee. Dr. Talmadge currently serves on the Boards of five private life science companies, holds 19 issued U.S. patents, and has authored numerous scientific articles. Dr. Talmadge is co-founder and Chief Science Officer of Kyphon, a minimally invasive spine company acquired by Medtronic in 2007. Until the acquisition, she served as a member of Kyphon's Board and Executive Vice President. From 1994-1998, she served as Kyphon's President, CEO and Treasurer. Prior to Kyphon, she held a variety of research and business positions at the biotechnology company Scios. Dr. Talmadge conducted post-doctoral research at Harvard University and Cold Spring Harbor Laboratory, and received a Ph.D. in Biochemistry from Harvard University.